Teva to Halt Phase 2 Emrusolmin Trial Over Lack of Efficacy
Teva Pharmaceuticals will halt its phase 2 TOPAS-M trial of the neurodegenerative drug emrusolmin over lack of efficacy.
Teva Pharmaceuticals will halt its phase 2 TOPAS-M trial of the neurodegenerative drug emrusolmin over lack of efficacy.